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MinireviewPathways to Parkinsonism
cessive PD locus, PARK6) and significantly overlappingMark R. Cookson*
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Like the other familial PD loci, DJ-1 mutations so farNational Institute on Aging
account for a small number of cases.National Institutes of Health
Do these early-onset cases tell us much about spo-Bethesda, Maryland 20892
radic, late-onset PD? I would argue that the overlap
between -synuclein, parkin, DJ-1, and idiopathic PD is
as strong as the overlap between idiopathic AD andA novel gene for Parkinson’s disease (PD), DJ-1, has
APP or presenilin mutations. Also, the phenotype ofbeen identified that encodes a multifunctional product
parkin cases includes later onset “typical” PD, and vari-with several known protein-protein interactions and
ability at the parkin and -synuclein loci contribute toeffects on gene expression. Here, I outline how it is
the risk of idiopathic disease (e.g., Farrer et al., 2001).possible to construct hypotheses that place DJ-1 in
What Is Known about DJ-1different relationships to the other known PD genes,
DJ-1 was cloned independently by three groups. DJ-1-synuclein and parkin. The identification of multiple
interacts with c-myc and increases cell transformationgenetic causes will provide further impetus to describe
in the presence of myc or h-ras (Nagakubo et al., 1997).the pathway leading to PD.
The rat homolog CAP1 is associated with infertility (Wa-
genfeld et al., 1998). DJ-1 inhibits the RNA binding activ-A New Gene for Parkinson’s Disease
ity of a 400 kDa multiprotein complex (which includesIn a recent issue of Science, Bonifati et al. describe the
glyceraldehyde-3-phosphate dehydrogenase) that is re-cloning of a gene for early-onset recessive Parkinson’s
sponsive to cAMP and stabilizes mRNA (Hod et al.,disease (PD) (Bonifati et al., 2002). This is the third gene
1999).to be identified as definitively causal in familial PD, the
DJ-1 also affects mRNA expression via protein-pro-other two being -synuclein and parkin. A mutation in
tein interactions with PIASx (Takahashi et al., 2001).UCHL1 has been implicated in one small family, and
PIASx interacts with the androgen receptor, inhibitingalthough the genetic evidence is relatively weak, func-
gene expression. DJ-1 binds to PIASx, thereby posi-tional data support this claim (Liu et al., 2002). The no-
tively regulating androgen receptor-controlled genes.menclature of the PD loci and descriptions of the phe-
PIASx is an E3-like enzyme that adds SUMO-1 to targetnotypes were reviewed by Gwinn-Hardy (2002), but
proteins, a small ubiquitin-like molecule that is criticalsome points are worth emphasizing. First, the mutations
in cellular signaling pathways. DJ-1 is itself sumoylatedin -synuclein are dominant, while parkin mutations are
at K130: for other proteins, reciprocal modifications ofusually recessive. Second, the phenotype in the -synu-
SUMO and ubiquitin (often at the same residue) controlclein patients is more than parkinsonism, including ex-
relative rates of protein degradation or translocationtensive -synuclein pathology throughout the CNS and
between different cellular compartments (Hegde andfeatures such as dementia. Parkin cases tend to be early
DiAntonio, 2002). Finally, DJ-1 has been found to shiftonset with prominent features such as dystonia and
to a more acidic isoform (pI 5.8) after treatment of cellshave an extended course. Therefore, parkin and -synu-
with paraquat (Mitsumoto et al., 2001). The nature ofclein mutations overlap phenotypically with sporadic
this modification is not clear, although direct oxidation
PD, but both are slightly different and distinctive from
of the protein has been suggested (Mitsumoto et al.,
each other. Mutations in -synuclein and UCHL1 are
2001). In summary, DJ-1 has multiple protein-protein
extremely rare, while mutations in parkin are more com- interactions and multiple possible functions. The known
mon in early-onset cases but still a small proportion of interactions of DJ-1 are summarized in Figure 1.
the total number of cases of PD (Gwinn-Hardy, 2002). Fitting DJ-1 in a Pathway Including -Synuclein
The DJ-1 gene has seven exons and encodes a 189 and Parkin
amino acid (20 kDa) protein. In one Dutch kindred, a The focus of this minireview is to outline how we can
large homozygous chromosomal deletion removes 4 kb incorporate DJ-1 into hypothetical pathways leading to
of genomic DNA, including the exon encoding the start neurodegeneration in PD. By “pathway,” I envision a
codon, while in an Italian family, there is an L166P point temporal sequence of events leading to cell loss. The
mutation. Critically, in both pedigrees, heterozygous in- key to understanding PD will be to determine the events
dividuals are unaffected, while homozygotes all have that start the process and those that maintain the pro-
disease. This segregation of two different mutations gressive nature of the disease. One reason for studying
supports the contention that they are pathogenic. The genetics is that, in these families, the root cause of
clinical phenotype of the two families is of early-onset disease is unambiguously the inherited mutation.
disease with typical parkinsonian symptoms, prolonged Any scheme that purports to comprehend the causal
course and good response to L-DOPA. Functional im- role of DJ1 in PD must include an understanding of the
aging indicates nigral cell loss, although pathological common effects of mutations in -synuclein and parkin.
material is not yet available. Overall, the picture of this A shared property of -synuclein mutants is that they
disease is very similar to parkin cases (and another re- form oligomers and protofibrils more readily than wild-
type protein (Conway et al., 2000), although there may
be other important shared properties. Parkin is an E3*Correspondence: cookson@mail.nih.gov
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Figure 1. Interactions and Modifications of
DJ-1
ubiquitin-protein ligase (see below), and mutations (Shimura et al., 2001). By keeping levels of -synuclein
below the threshold needed to form oligomeric species,mainly result in decreased enzyme efficiency. There are
several ways to connect the bare bones of observations parkin activity could prevent damaging effects on neu-
rons. Several laboratories have shown that mutant formsinto a skeleton of a pathway, but two strong theories
are oxidative events and dysfunction of the proteasome of -synuclein inhibit proteasome function through an
unknown mechanism, which we have recently confirmedsystem.
From the rusting of nails to the function of mitochon- and further shown that parkin is protective against toxic-
ity of mutant -synuclein (Petrucelli et al., 2002, anddria, free radicals and other strong oxidants play a role
that varies between beneficial and detrimental. Bonifati references therein). UCHL1 has a ligase activity that
promotes addition of ubiquitin to preformed ubiquitinet al. suggest “it is possible that DJ-1 participates in the
oxidative stress response by directly buffering cytosolic chains on proteins (Liu et al., 2002). Therefore, parkin,
-synuclein, and UCHL1 mutations share effects on pro-redox changes, and/or by modulating gene expression
at transcriptional and post-transcriptional levels.” There teosome function. It is also worth noting that an effect of
reduced mitochondrial complex I activity (e.g., rotenone,is evidence that oxidative events occur during the
course of PD. Catecholamines in the cytosol of vulnera- MPTP) is to decrease cellular ATP levels and may indi-
rectly inhibit the highly ATP-dependent proteasome.ble neurons can promote oxidative events leading to
cell death, including enhancing -synuclein toxicity (Xu The weakness, but perhaps also the strength, of argu-
ments for both oxidative stress and proteasome inhibi-et al., 2002). The mitochondrial complex I inhibitors
MPTP and rotenone cause damage to nigral neurons by tion is that they imply a commonality between different
neurodegenerative disorders. The presence of oxidativemechanisms involving oxidation (for review, see Dawson
et al., 2002). Interestingly, the L166P point mutation in stress in many diseases may mean that this is a shared
but late event. Likewise, decreased proteasome activityDJ-1 causes it to mislocalize to mitochondria after over-
expression in vitro (Bonifati et al., 2002). -Synuclein can result from the overexpression of mutant huntingtin
(Bence et al., 2001) and other mutant proteins, whichmutations sensitize cells to oxidative events, and
-synuclein is also a target for oxidative modifications, complicates the argument that ubiquitin-mediated pro-
tein degradation has a specific effect in PD. The un-such as nitrosylation. The effects of parkin mutations
on oxidative stress are less obvious, but maybe parkin folded protein response (UPR) can be induced by the
parkin substrate PaelR1 (Imai et al., 2001), but again,is important in controlling the degradation of oxidized
or damaged proteins. the UPR may be a common mechanism for neurodegen-
erative diseases (Sherman and Goldberg, 2001). Per-This leads us to a further hypothesis, that the underly-
ing dysfunction in PD is a failure of ubiquitin-mediated haps misfolded proteins trigger all of these diseases,
with different proteins for each one, but the mechanismsprotein degradation. The strongest evidence that protein
degradation is at fault comes from the observed E3 that follow from such events and the effects on different
neurons are not understood. It is possible that specificligase activity of parkin. Decreasing this activity would
result in the accumulation of target proteins such as the protein partners in different neurons change either the
rate of accumulation of mutant proteins or shift cellularER-resident PaelR1, which is directly toxic in cell culture
(Imai et al., 2001), cdc-rel1 (Zhang et al., 2000), syn- response to these events.
One type of cellular response is via signaling pathwaysphilin-1 (Ribeiro et al., 2002), or glycosylated-synuclein
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that promote neuronal survival, which could vary be- might also consider whether DJ-1 plays any role in other
neurological diseases.-Synuclein was first cloned fromtween different neuronal types. As discussed above,
DJ-1 can be sumoylated and interacts with other sumoy- AD brain, although its role in that disease is not clear.
The interaction of DJ-1 with the androgen receptor hintslating enzymes. Ubiquitination can control synaptic for-
mation, development, and plasticity as well as axon at a provocative but murky link to Kennedy’s disease,
caused by a triplet repeat expansion in the androgenguidance, while SUMO is known to modulate neuronal
activity via CAMKII (Hegde and DiAntonio, 2002). Thus, receptor gene.
In terms of experimental paradigms, we need to devel-DJ-1 and parkin could be part of a signaling pathway
that controls synaptic events. Intriguingly, some of the op DJ-1 knockout animals to model the loss-of-function
alleles or knockdown models using antisense. Wouldtargets for sumoylation by DJ-1-interacting PIAS pro-
teins are the septin family of cytoskeletal proteins, at these have a phenotype, and would they enhance the
phenotype in, for example, mice transgenic for mutantleast in yeast (Johnson and Gupta, 2001). A target for
parkin’s E3-ligase activity is the mammalian septin ho- -synuclein? This is perhaps the time to distinguish the
effects of manipulating PD genes on both oxidativemolog cdc-rel1, which is associated with synapses
(Zhang et al., 2000). Synphilin-1 is enriched in synaptic stress and proteasome inhibition. These could be sepa-
rated by comparing the modulatory effects of expres-compartments (Ribeiro et al., 2002), as is parkin (Fallon
et al., 2002). -Synuclein is also associated with syn- sion of antioxidant genes with molecular chaperones
such as HSPs (see references in Sherman and Goldberg,apses, and knockout studies suggest it regulates a pool
of reserve vesicles (Cabin et al., 2002, and references 2001) on-synuclein, parkin, and DJ-1. We should deter-
mine if DJ-1 protects cells against mutant -synucleintherein). Therefore, a promising hypothesis is that the
real link between these proteins is that they all have or proteasome inhibitors, as we have shown for parkin
(Petrucelli et al., 2002), and compare this to any abilityeffects on regulation of signaling pathways at synapses.
Other signaling pathways may impact on the same pro- of DJ-1 to protect against oxidative damage induced by
MPTP, rotenone, or other dopaminergic toxins. Further-cesses: for example, phosphorylation of -synuclein oc-
curs and is associated with decreased solubility and more, we have to explain how different neurons react
to these damaging stimuli. For instance, catecholamin-ubiquitination (Hasegawa et al., 2002).
The hypotheses of oxidative stress, protein turnover, ergic neurons are sensitive to both -synuclein muta-
tions and proteasome inhibition (Petrucelli et al., 2002).and altered signaling make distinct predictions, al-
though they are not mutually exclusive. I suspect that Expression of the protein would be helpful to deter-
mine some of its normal functions. Given that DJ-1 inter-in time we will be able to distinguish the primary events
from those that occur downstream. The inhibition of the acts with a number of other proteins, including the E3-
like enzyme PIASx, a worthwhile experiment would beproteasome may be a result of signaling pathways gone
awry, with the accumulation of oxidatively damaged pro- to find out if DJ-1 regulates or modifies parkin activity
or expression. Equally important are experiments to de-teins being a tertiary event. Perhaps DJ-1 does not fit
into any of the above pathways and might lead us to termine if DJ-1 is either ubiquitinated via ubiquitin’s
Lys63 for signaling or polyubiquitinated via Lys48 link-new ideas about PD. The final section of this minireview
will discuss how we might begin to disentangle these ages for degradation by the proteasome (for a review
of the different ubiquitin linkages, see Marx, 2002). Asthreads of evidence and reconstruct the pathway for PD.
Unanswered Questions about DJ-1 DJ-1 and -synuclein are both proteins with multiple
interactions, it is feasible that they could interact withWhat will experimenters in the PD field want to do with
the discovery of DJ-1 mutations? Because there is so each other as well. The intriguing mislocalization of
L166P DJ-1 to mitochondria requires further clarifica-little known about DJ-1, there are a number of simple
questions. We do not know the detailed distribution of tion. If there are other point mutations, it will be critical
to know if they all have this effect and what biophysicalDJ-1 in the CNS, such as expression in nigral neurons
or association with cytoskeletal or synaptic elements. properties drive the interaction with mitochondria.
The identification of DJ-1 opens up new doors forIn non-neuronal cells in culture, DJ-1 immunoreactivity
is associated with the cytoskeleton (Hod et al., 1999) extended genetic analysis. Initially, DJ-1 should be ex-
cluded as a candidate in the other known PD loci.and nucleus (Nagakubo et al., 1997). Cytoskeleton-asso-
ciated RNA binding proteins are often involved in mRNA Screening of series of all early-onset PD cases will be
important to ascertain the prevalence of DJ-1 mutations.sorting, and in neurons, targeting of mRNA species to
dendrites is critical to the regulation of gene expression. DJ-1 might be a risk factor for sporadic PD if there
are functional variants that, in combination with parkin,Therefore, comprehensive descriptions of the DJ-1 lo-
calization may give hints to function. We also want to -synuclein, and UCHL1, lead to damaging processes
in nigral neurons.identify the transcriptional complement induced by DJ-1.
The characterization of the paraquat-induced acidic It is too early to predict the answers to the questions
articulated here, but the following points are critical: (1)isoform of DJ-1 will be of interest. Is it present in PD
patients or in models such as rotenone or MPTP treated we have to understand the shared properties of the
known pathogenic mutations in the various identifiedanimals? Given that Lewy bodies are accumulations of
many proteins, including -synuclein (and possibly par- PD genes and how they impact on common cellular
pathways; (2) any explanation should also address se-kin and synphilin), it is important to know whether DJ-1
is in Lewy bodies. Autopsy material from DJ-1 cases lectivity in effects, noting the early and severe sensitivity
of nigral neurons to the disease process in PD; and (3) wewill allow us to determine if Lewy body formation occurs
in these patients and (in the case of L166P) confirm need to dissociate the primary events from secondary
occurrences and better understand the progressive na-the mitochondrial localization of the mutant protein. We
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ture of this disorder. The answers to these questions
will be increasingly important in our attempts to under-
stand the pathways leading to parkinsonism.
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